Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines - Kohrt, Lisa-Madeleine; Gladbach, Yvonne S.; Ernst, M.; Hamed, M.; Roolf, C.; Sender, S.; Beck, J.; Schütz, E.; Fischer, Sarah; Struckmann, Stephan; Junghanss, C.; Fuellen, G.; et al. (Cancer cell international, 2020)
Gesehen am 15.10.2020